These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20458309)

  • 1. Research at the interface of industry, academia and regulatory science.
    Mattes WB; Walker EG; Abadie E; Sistare FD; Vonderscher J; Woodcock J; Woosley RL
    Nat Biotechnol; 2010 May; 28(5):432-3. PubMed ID: 20458309
    [No Abstract]   [Full Text] [Related]  

  • 2. Biomarkers on a roll.
    Nat Biotechnol; 2010 May; 28(5):431. PubMed ID: 20458308
    [No Abstract]   [Full Text] [Related]  

  • 3. The drug regulatory system of the United States Food and Drug Administration: a defense of current requirements for safety and efficacy.
    Simmons HE
    Int J Health Serv; 1974; 4(1):95-107. PubMed ID: 4829901
    [No Abstract]   [Full Text] [Related]  

  • 4. A roadmap for biomarker qualification.
    Warnock DG; Peck CC
    Nat Biotechnol; 2010 May; 28(5):444-5. PubMed ID: 20458313
    [No Abstract]   [Full Text] [Related]  

  • 5. Regulatory science and the role of the regulator in biomedical innovation.
    Honig PK; Huang SM
    Clin Pharmacol Ther; 2012 Mar; 91(3):347-52. PubMed ID: 22343804
    [No Abstract]   [Full Text] [Related]  

  • 6. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium.
    Dieterle F; Sistare F; Goodsaid F; Papaluca M; Ozer JS; Webb CP; Baer W; Senagore A; Schipper MJ; Vonderscher J; Sultana S; Gerhold DL; Phillips JA; Maurer G; Carl K; Laurie D; Harpur E; Sonee M; Ennulat D; Holder D; Andrews-Cleavenger D; Gu YZ; Thompson KL; Goering PL; Vidal JM; Abadie E; Maciulaitis R; Jacobson-Kram D; Defelice AF; Hausner EA; Blank M; Thompson A; Harlow P; Throckmorton D; Xiao S; Xu N; Taylor W; Vamvakas S; Flamion B; Lima BS; Kasper P; Pasanen M; Prasad K; Troth S; Bounous D; Robinson-Gravatt D; Betton G; Davis MA; Akunda J; McDuffie JE; Suter L; Obert L; Guffroy M; Pinches M; Jayadev S; Blomme EA; Beushausen SA; Barlow VG; Collins N; Waring J; Honor D; Snook S; Lee J; Rossi P; Walker E; Mattes W
    Nat Biotechnol; 2010 May; 28(5):455-62. PubMed ID: 20458315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug discovery-background and foreground.
    Tishler M
    Clin Pharmacol Ther; 1973; 14(4):479-86. PubMed ID: 4723254
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmaceutical drugs-the good and the not so good: together, we can make it better.
    Campbell AW
    Altern Ther Health Med; 2014; 20(1):9-11. PubMed ID: 24445351
    [No Abstract]   [Full Text] [Related]  

  • 9. An uncertain future for cardiovascular drug development?
    Garber AM
    N Engl J Med; 2009 Mar; 360(12):1169-71. PubMed ID: 19297568
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug development: how academia, industry and authorities interact.
    Garattini S; Perico N
    Nat Rev Nephrol; 2014 Oct; 10(10):602-10. PubMed ID: 25092151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Disposition Issues in CKD: Implications for Drug Discovery and Regulatory Approval.
    Tieu A; House AA; Urquhart BL
    Adv Chronic Kidney Dis; 2016 Mar; 23(2):63-6. PubMed ID: 26979144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CONTROL OF DRUG TOXICITY IN THE UNITED STATES OF AMERICA.
    WESTON JK; WESTON K
    Practitioner; 1965 Jan; 194():16-21. PubMed ID: 14259685
    [No Abstract]   [Full Text] [Related]  

  • 13. Program seeks to enlist physicians to flag questionable promotion of drugs.
    Mitka M
    JAMA; 2010 Jul; 304(1):28-9. PubMed ID: 20606140
    [No Abstract]   [Full Text] [Related]  

  • 14. European initiative towards quality standards in education and training for discovery, development and use of medicines.
    Klech H; Brooksbank C; Price S; Verpillat P; Bühler FR; Dubois D; Haider N; Johnson C; Lindén HH; Payton T; Renn O; See W
    Eur J Pharm Sci; 2012 Apr; 45(5):515-20. PubMed ID: 22178534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health.
    Gostin LO
    JAMA; 2009 May; 301(19):2036-7. PubMed ID: 19454642
    [No Abstract]   [Full Text] [Related]  

  • 16. Industry is more alarmed about reproducibility than academia.
    Bespalov A; Barnett AG; Begley CG
    Nature; 2018 Nov; 563(7733):626. PubMed ID: 30487623
    [No Abstract]   [Full Text] [Related]  

  • 17. The HEALTH Act's FDA defense to punitive damages: a gift to drug makers or to the public?
    Levy E
    Fordham Law Rev; 2006 Mar; 74(4):2425-60. PubMed ID: 17115481
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug Regulation and Pricing--Can Regulators Influence Affordability?
    Eichler HG; Hurts H; Broich K; Rasi G
    N Engl J Med; 2016 May; 374(19):1807-9. PubMed ID: 27168431
    [No Abstract]   [Full Text] [Related]  

  • 19. Pfizer reaches out to academia--again.
    Ratner M
    Nat Biotechnol; 2011 Jan; 29(1):3-4. PubMed ID: 21221077
    [No Abstract]   [Full Text] [Related]  

  • 20. Drugs, industry, and academia.
    Fitzgerald GA
    Science; 2008 Jun; 320(5883):1563. PubMed ID: 18566251
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.